TO THE EDITORS
I just read the commentary by McMahon et al.1 I very much support their arguments and would like to share a 30-year-old anecdote.
In the early 1970s, as a graduate student at Carnegie-Mellon University, I was involved in a project that applied cost-effectiveness analysis to medical screening tests in use at that time, one of which was Pap smears. The faculty concluded that cervical cancer screening was not cost effective, based on a mathematical model that used the low overall incidence of cervical cancer, among many other inputs. I and another student independently re-did the analysis, separating the data by ethnicity and age. We found that screening guidelines should vary by both the woman's ethnicity and age.
Thirty years on, this concept of targeting screening or treatment to those for whom it would most benefit and not providing it to those for whom it would least benefit is still not accepted. Some may say this is rationing–if so, it is rationing based on clinical and epidemiologic information. In a society with limited resources for government programs such as Medicare and Medicaid, and with 48 million people without health insurance coverage, rationing based on clinical and epidemiologic information is preferable to rationing based on economic criteria.
W. P. Carey School of Business
Bradford Kirkman-Liff, DrPH
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
February 20th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.
Read More
Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans
February 10th 2025This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Read More